Trump’s 100% Drug Tariff Hits Canada Today While EU and Japan Get a 15% Cap

35,000+ smart investors are already getting financial news, market signals, and macro shifts in the economy that could impact their money next with our FREE weekly newsletter. Get ahead of what the crowd finds out too late. Click Here to Subscribe for FREE.

A major new U.S. pharmaceutical tariff takes effect on September 29, putting Canadian-made patented medicines in a sharply different position from comparable products made in several American trading partners. Under President Donald Trump’s pharmaceutical Section 232 regime, covered patented drugs and pharmaceutical ingredients can face a 100% U.S. tariff, while products from the European Union and Japan are generally capped at 15%.

The headline rate is real, but it is not a blanket 100% tax on every Canadian medicine crossing the border. Generics are currently exempt, some specialty medicines can qualify for zero tariffs, and pharmaceutical companies with approved U.S. investment or pricing agreements can receive substantially lower rates. Those details could determine which Canadian producers feel the greatest impact. 

What Changed at 12:01 a.m. on September 29

The September 29 deadline comes from an April 2 presidential proclamation issued under Section 232 of the Trade Expansion Act of 1962. The measure established a default 100% ad valorem duty on specified patented pharmaceuticals and associated ingredients. For 17 companies identified earlier by Washington, the regime began on July 31. For companies outside that initial group, the effective date was set at 12:01 a.m. Eastern time on September 29. Canada’s Trade Commissioner Service specifically warned Canadian exporters that the broader 100% pharmaceutical tariff would enter into force on that date. 

That distinction matters because the tariff is aimed primarily at patented medicines rather than the entire pharmacy shelf. The Commerce Department confirmed in its September implementation guidance that generic pharmaceuticals and their associated ingredients remain outside the Section 232 pharmaceutical tariffs for now. In practical terms, a Canadian manufacturer exporting an off-patent generic may therefore face very different treatment from a company shipping a patented branded therapy manufactured in Canada.

Why Canada Faces 100% While the EU and Japan Stop at 15%

The biggest Canadian concern is not simply the size of the headline tariff, but the difference in treatment between trading partners. The presidential proclamation explicitly sets a 15% rate for covered patented pharmaceutical products originating in Japan, the European Union, South Korea, Switzerland and Liechtenstein. The United Kingdom receives separate preferential treatment. Canada was not included in that 15% group, leaving qualifying Canadian patented pharmaceutical imports exposed to the default rate unless another exemption applies.

The EU and Japanese treatment reflects trade agreements Washington previously negotiated with those economies. The 2025 U.S.-EU framework, for example, committed the United States to an all-inclusive tariff ceiling of 15% on pharmaceutical products subject to future Section 232 measures. The U.S.-Japan agreement similarly established a broader 15% tariff framework for Japanese goods. The April 2026 pharmaceutical proclamation formally carried those commitments into the new drug tariff system. The result is a striking gap: a covered medicine originating in Canada could theoretically attract a 100% duty while a comparable covered product originating in the EU or Japan is limited to 15%. 

Canada’s Exposure Is Large, but Uneven

Canada has meaningful pharmaceutical trade at stake. Innovation, Science and Economic Development Canada reports that Canadian pharmaceutical exports totalled roughly C$14.5 billion in 2025. The United States accounted for 70.4% of those exports, making it overwhelmingly Canada’s largest foreign market for pharmaceutical production. That works out to roughly C$10 billion in annual exports tied to the U.S. market, although only part of that trade falls within the specific patented-drug categories covered by the new 100% regime.

The sector also has a substantial domestic footprint. Pharmaceutical manufacturing employed about 35,700 people in Canada in 2025, up nearly 10% over five years. ISED counted 431 pharmaceutical manufacturing establishments with employees, and more than four-fifths of establishments had fewer than 100 workers. Ontario and Quebec contain the largest concentrations of pharmaceutical manufacturing businesses. That means tariff exposure is not simply an issue for multinational drug giants. Contract manufacturers, ingredient suppliers and smaller Canadian facilities can also depend on production runs ultimately destined for American customers. 

The 100% Rate Does Not Apply to Every Medicine

The exemptions are extensive enough that describing the policy simply as a “100% tariff on Canadian drugs” misses important details. Generic pharmaceuticals, biosimilars and their associated ingredients are currently exempt from the pharmaceutical Section 232 tariff. Companies with Commerce-approved plans to move production to the United States can qualify for a 20% rate, while companies combining approved onshoring plans with certain U.S. drug-pricing agreements can qualify for zero tariffs through January 20, 2029. 

Washington has also carved out several categories of specialty medicine. Commerce identified orphan drugs used exclusively for rare diseases, nuclear medicines, plasma-derived therapies, fertility drugs, cell and gene therapies, antibody-drug conjugates and certain emergency medical countermeasures as products that may receive zero-tariff treatment under specified conditions. A September Commerce notice listed the EU and Japan among jurisdictions automatically eligible for that specialty treatment, but Canada was not on the jurisdiction list. Canadian products can still seek relief when Commerce determines that an import addresses an urgent U.S. health need, meaning individual medicines could receive exceptions even without Canada receiving country-wide preferential treatment.

The Pressure Falls Heaviest on Where Companies Choose to Manufacture

The structure of the tariff makes investment decisions almost as important as trade flows. The Trump administration says the Section 232 action is designed to reduce American dependence on foreign pharmaceutical manufacturing. Its Commerce investigation concluded that the country relied heavily on imported patented medicines and pharmaceutical ingredients, and the administration explicitly paired the tariff with incentives for companies to build production capacity in the United States. 

For Canadian facilities, that creates a longer-term competitive issue. A company deciding where to manufacture the next generation of a patented medicine now has a powerful tariff incentive to place capacity inside the United States or within a country receiving preferential treatment. Canada still has advantages including an established life-sciences workforce, research infrastructure and geographic proximity to the American market, but proximity alone does not eliminate a Section 232 tariff. The Canadian pharmaceutical sector spent about C$1.29 billion on business research and development in 2024, while employment continued expanding through 2025. Whether those investment trends continue will partly depend on how individual companies adapt to the new U.S. rules. 

A 100% Tariff Does Not Mean Drugstore Prices Automatically Double

A tariff is charged on the imported product’s customs value, and the importer of record is generally responsible for paying it. That does not mean a medicine costing $500 at the pharmacy automatically becomes $1,000. Manufacturers, wholesalers, insurers, pharmacy benefit managers and health programs operate through complicated pricing arrangements, rebates and contracts. Some companies may absorb part of a tariff, others may renegotiate prices, and some may shift production or sourcing. Canada’s Trade Commissioner Service similarly notes that although the importer pays the tariff, contracts between importers and exporters can determine how the commercial burden is ultimately shared. 

Research also illustrates why the relationship between tariff rates and final medicine prices is not one-for-one. A 2025 Health Affairs Scholar study modelled tariffs on imported pharmaceutical ingredients and found that, under its assumptions, a hypothetical worldwide 100% tariff on APIs would increase average prices for the studied U.S.-made generic prescriptions by about 30%, rather than 100%. That study examined a different market from the current patented-drug tariff, and generics are presently exempt, so its estimates should not be treated as a forecast. It does demonstrate how production costs and tariff pass-through can produce effects very different from the headline rate. 

CUSMA Does Not Provide Canada With an Escape Hatch

Canadian companies have frequently relied on CUSMA compliance to avoid other U.S. tariffs, but pharmaceuticals are different under this measure. Canada’s Trade Commissioner Service says explicitly that there is no CUSMA-compliant exemption from the Section 232 tariff on covered patented pharmaceuticals and associated ingredients. A Canadian medicine can therefore satisfy North American rules of origin and still face the pharmaceutical tariff. 

That puts the pharmaceutical measure in the same broad category as several other U.S. sector-specific Section 232 actions for which CUSMA status does not automatically eliminate duties. It also helps explain why the comparison with Europe and Japan is significant. Canada already has one of the most deeply integrated trading relationships with the United States, and more than 99.9% of bilateral trade is conducted in tariff lines covered by CUSMA preferences, according to Canadian government guidance. Yet Washington has separately negotiated country-specific treatment for pharmaceuticals with the EU and Japan while leaving Canadian patented medicines outside the 15% pharmaceutical cap. 

What Comes Next for Canada and Drugmakers

The immediate response is likely to vary company by company because Washington has deliberately created several routes to lower tariffs. Pharmaceutical manufacturers can pursue U.S. onshoring commitments, negotiate qualifying pricing agreements, examine whether individual medicines fall within specialty-product exemptions, or seek an urgent-health-need determination from the Commerce Department. Commerce says those urgent-health applications will be evaluated individually with input from U.S. health and trade officials, and the program accepts submissions on an ongoing basis. 

Canada enters this new phase while the broader bilateral trade relationship remains strained. Prime Minister Mark Carney suspended Canada-U.S. trade negotiations in August after saying proposed U.S. terms were unacceptable, and Canadian officials continued meeting with industry representatives in September to discuss the trade dispute. Ottawa has also directed affected companies toward tariff assistance and export diversification programs. Canada’s September counter-tariffs currently concentrate on sectors including steel, dairy, appliances, agricultural equipment, pulp and paper, plastics and electronics rather than mirroring the pharmaceutical measure directly. For Canadian drugmakers, the central question now is less whether the 100% headline rate exists—it does—and more how much pharmaceutical trade ultimately remains exposed after all of the exemptions, company agreements and investment decisions are counted.

 

This Options Discord Chat is The Real Deal

While the internet is scoured with trading chat rooms, many of which even charge upwards of thousands of dollars to join, this smaller options trading discord chatroom is the real deal and actually providing valuable trade setups, education, and community without the noise and spam of the larger more expensive rooms. With a incredibly low-cost monthly fee, Options Trading Club (click here to see their reviews) requires an application to join ensuring that every member is dedicated and serious about taking their trading to the next level. If you are looking for a change in your trading strategies, then click here to apply for a membership.